Biogen ($BIIB) $18.9 Million Investor Settlement

Biogen has agreed to a proposed $18.9 million settlement to resolve investor claims that it misled the market about Aduhelm’s Medicare coverage, payer support, and commercial launch readiness after FDA approval.

Outline:

On June 7, 2021, the FDA approved Aduhelm as Biogen prepared for a major launch. On June 8, 2021, Biogen told investors it had engaged with payers and that Medicare fee-for-service coverage was automatically presumed with FDA approval. On June 24, 2021 and July 15, 2021, the market learned more about pricing and reimbursement uncertainty around Aduhelm. The case has now moved to a proposed $18.9 million settlement.

Timeline:

• June 7, 2021: The FDA granted accelerated approval for Aduhelm.

• June 8, 2021: Biogen said it had engaged with payers on Aduhelm and stated that Medicare fee-for-service coverage was automatically presumed with FDA approval.

• June 24, 2021: Biogen said it was addressing Aduhelm’s price, healthcare-budget impact, and patient access as officials and reports highlighted Medicare coverage uncertainty.

• July 15, 2021: Reports said major insurers were waiting for CMS guidance and that coverage was likely to remain limited until CMS completed its review.

• June 5, 2026: The parties reached an agreement in principle to settle the case for $18.9 million.

Background:

Biogen is a biotechnology company focused on neurological diseases. In June 2021, it won FDA accelerated approval for Aduhelm, which was presented as the first FDA-approved treatment intended to address the progression of Alzheimer’s disease.

Investors say Biogen then gave the market an overly confident picture of Aduhelm’s commercial setup. According to the notice, the case centers on statements that Biogen had engaged with payers on Aduhelm and that Medicare fee-for-service coverage was automatically presumed after FDA approval.

The dispute focuses on reimbursement and launch readiness. Investors allege Aduhelm did not have the level of payer support and Medicare clarity that Biogen’s statements suggested, which made the launch less secure than the market was led to believe.

The source identifies June 24, 2021 and July 15, 2021 as the key corrective-disclosure dates. Investors say those events revealed more of the reimbursement and coverage uncertainty surrounding Aduhelm and caused the stock to trade down from allegedly inflated levels.

The parties later litigated the case through dismissal proceedings, class certification, discovery, expert work, summary judgment, and mediation before agreeing to a proposed $18.9 million settlement. The notice says that settlement, if approved, will resolve the claims in the action.

What Can Investors Expect Now?

Biogen has agreed to a proposed $18.9 million settlement to resolve investor claims that it misled the market about Aduhelm’s Medicare coverage, payer support, and commercial launch readiness after FDA approval.

If you were damaged due to this situation, you can file for a payout and get your share of the settlement. You can check if you are eligible and other details in the FAQ section.